NSE · MARKSANS · Pharmaceuticals
Marksans Pharma Limited
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹321 Cr with net profit ₹69 Cr — a 21.5% net margin, versus 13.78% the period before.
Shareholding
As of 2026-06-30
- Promoter43.87%
- Public32.47%
- FII17.47%
- DII6.19%
2,46,635 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 2.26× from low to high.
Risk flags
Derived from disclosed data
No flags raised by the data.
Peer comparison
Pharmaceuticals - Indian - Formulations · ranked #8 of 50 by market cap · medians across 43 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Torrent Pharmaceuticals Limited | ₹1,88,872 Cr | 84.65 | 22.5 | 25.49% | 13.95% |
| Gland Pharma Limited | ₹48,208 Cr | 42.07 | 4.65 | 9.92% | 16.78% |
| Ajanta Pharma Limited | ₹44,153 Cr | 38.91 | 9.77 | 23.33% | 19.65% |
| Rubicon Research Limited | ₹30,382 Cr | 105.42 | 23.61 | 19.14% | 14.89% |
| Caplin Point Laboratories Ltd. | ₹20,940 Cr | 31.47 | 6.21 | 17.88% | 29.09% |
| Shilpa Medicare Ltd. | ₹18,798 Cr | 66.1 | 7.26 | 9.39% | 17.67% |
| Eris Lifesciences Limited | ₹18,785 Cr | 28.6 | 4.82 | 15.87% | 20.04% |
| Marksans Pharma Limited(this company) | ₹14,927 Cr | 28.89 | 4.92 | 13.82% | 16.29% |
| Bliss GVS Pharma Ltd. | ₹7,666 Cr | 55.67 | 6.44 | 10.82% | 13.55% |
| Senores Pharmaceuticals Limited | ₹6,757 Cr | 53.47 | 7.24 | 12.36% | 18.59% |
AI analysis
AI-generated · google/gemini-2.5-flashMarksans Pharma Limited is listed on the Indian markets with a market capitalization of Rs 11796 Cr. It operates in the Pharmaceuticals sector. The company reported a revenue growth of 20.46% and a profit margin of 14.16%. The book value per share is Rs 66.71, with an EPS of Rs 9.22. The company's stock traded between a 52-week high of Rs 281.6 and a 52-week low of Rs 155. It has a debt-to-equity ratio of 0.12.
Positives
- +Revenue grew by 20.46%.
- +Debt-to-equity ratio is low at 0.12.
- +Promoter shareholding in June 2026 was 43.87%, with no shares pledged.
Negatives
- −Promoter shareholding has decreased from 48.2495% in March 2017 to 43.8742% in June 2026.
- −Quarterly EPS figures are not disclosed for any period in the provided data.
- −The dividend yield is not available in the given data (missing 'dividendYield').
Financial performance
For the financial year ending March 2025, Marksans Pharma Limited reported a revenue of Rs 2693.221 Cr and a net profit of Rs 380.575 Cr, with an EPS of Rs 8.4. In the latest quarterly results for March 2026, the company's revenue was Rs 856.11 Cr and net profit was Rs 148.13 Cr.
Profitability & returns
The company’s profitability is indicated by a profit margin of 14.16%. The Return on Equity (ROE) stands at 13.82%, and the Return on Capital Employed (ROCE) is 17.3674%. The Earnings Per Share (EPS) for the company is Rs 9.22.
Balance sheet
Marksans Pharma Limited maintains a low debt-to-equity ratio of 0.12. The book value per share is reported as Rs 66.71. The company has a market capitalization of Rs 11796 Cr.
Ownership & pledges
The total institutional holding stands at 23.6581%. There are no promoter shares pledged.
Regulatory & surveillance
The company is not currently under any surveillance measure based on the provided data.
Data as of — price: 2026-09-12 · financials: Jun 26 · shareholding: Jun 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.